Vestcor Inc Purchases 4,887 Shares of Edwards Lifesciences Co. (NYSE:EW)

Vestcor Inc lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 44.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,793 shares of the medical research company's stock after purchasing an additional 4,887 shares during the period. Vestcor Inc's holdings in Edwards Lifesciences were worth $1,169,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in EW. Versor Investments LP increased its stake in Edwards Lifesciences by 102.5% during the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock worth $294,000 after acquiring an additional 2,255 shares during the period. GSA Capital Partners LLP bought a new position in Edwards Lifesciences during the 3rd quarter worth $481,000. MQS Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth $245,000. Oppenheimer & Co. Inc. increased its stake in Edwards Lifesciences by 3.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company's stock worth $2,520,000 after acquiring an additional 1,441 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. increased its stake in Edwards Lifesciences by 8.9% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,140 shares of the medical research company's stock worth $1,197,000 after acquiring an additional 1,480 shares during the period. Institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,303 shares of company stock valued at $3,715,776. Corporate insiders own 1.29% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent research reports. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Finally, Truist Financial reaffirmed a "hold" rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Trading Up 0.7 %

EW traded up $0.53 during midday trading on Wednesday, hitting $70.87. 5,167,268 shares of the company were exchanged, compared to its average volume of 4,543,256. The firm has a market capitalization of $41.66 billion, a P/E ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm's 50 day moving average price is $71.61 and its 200-day moving average price is $70.35. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.